Last mentioned: Mar 6, 2026
Phase I Initiation
First human subject enrolled and dosed in the Phase I clinical trial.
Out-Licensing Deal
TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.
Candidate Discovery
Insilico Medicine identifies ISM4808 using generative AI models.
Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
This page surfaces every story mentioning TaiGen Biopharmaceuticals across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where TaiGen Biopharmaceuticals was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |